Speaker Profile
PMWC PIONEER AWARD
Outstanding contributions to precision medicine include analyzing large-scale biomedical data, uncovering novel insights to improve patient care, and impacting the field through research on big data analysis, drug repurposing, biomarker discovery, patient stratification, and data-driven clinical decision support
MD, PhD, Institute Director and Distinguished Professor, UCSF
Biography
Atul Butte is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and Director of the Bakar Computational Health Sciences Institute at UCSF. Dr. Butte is also the Chief Data Scientist over all 6 academic health centers and 10 hospitals of the University of California Health System, the eighth largest by revenue in the United States. Dr. Butte has been continually funded by NIH for 25 years, is an inventor on 24 patents, and has authored over 300 publications, with research repeatedly featured in the New York Times and Wall Street Journal. Dr. Butte was elected into the National Academy of Medicine in 2015 and was recognized by the Obama Administration as a White House Champion of Change in 2013. Dr. Butte is also a cofounder of three investor backed data driven companies: Personalis (IPO, 2019), medical genome sequencing, Carmenta (acquired by Progenity, 2015), pregnancy complication diagnostics, and NuMedii, finding new drugs using AI.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair:
- William Oh, Mount Sinai
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.
Sessions:
- PMWC 2024 Award Ceremony
Pioneer Honoree: Atul Butte, UCSF
- Opening Talk: Pioneering the Next Decade: The Transformative Potential of Real-World Evidence/Data
- William Oh, Mount Sinai
- Strategies to Enhance Data Sharing in Medical Research (PANEL)
Chair: Amar Das, Guardant Health
- Paul Boutros, UCLA
- Ziad Obermeyer, UC Berkeley
- George Sledge, Caris Life Sciences
- Erica Galvez, Manifest MedEx - Data Privacy and Security in RWE/D (PANEL)
Chair: Deven McGraw, Invitae
- Christopher Boone, Oracle
- John Kalafut, Asher Orion Group
- Susan Stayn, Stanford
- Jessica Santos, Oracle - Using RWD to Accelerate Precision Medicine Product Development
- Mark Watson, Guardian Research Network
- Multi-Modal Datasets & RWE/D: Pioneering Tools for Accelerated Biomedical Research (PANEL)
Chair: Ilyana Rosenberg, Microsoft
- Charlene Son Rigby, STXBP1 Foundation
- John Wilbanks, Broad Institute
- Tristan Naumann, Microsoft - Leveraging RWE/D in Lupus: Using RNA Data and Predictive AI to Enhance Patient Care Decisions (PANEL)
Chair: Amrie Grammer, Ampel Biosolutions
- Ajay Nirula, Eli Lilly
- Pete Schafer, Bristol Myers Squibb - Accelerating Drug Development Approvals Using RWE/D (PANEL)
Chair: Mika Newton, xCures
- Leo Russo, Pfizer
- Eric Schadt, Pathos AI
- Ashley Brenton, Optum
- Nasha Fitter, Invitae - CVS Health Real World Evidence – Updates and New Directions in RWE
Chair: Alexandra Berk, CVS Health
- Kate Rosenbluth, Cala Health - Regulatory Challenges in RWE (PANEL)
Chair: Susan Winkler, Reagan-Udall Center
- Mei Sheng Duh, Analysis Group
- Rachael Fones, IQVIA
